What is claimed as the invention is:

- 1. A pharmaceutical composition suitable for administration to a human, comprising alloactivated lymphocytes in a compatible pharmaceutical excipient.
- 2. The composition of claim 1, comprising lymphocytes from at least two different humans.
- 3. The composition of claim 2, comprising lymphocytes from at least three different humans.
- 4. The composition of claim 3, comprising lymphocytes from at least four different humans.
- 5. The composition of claim 2, wherein lymphocytes from at least one of the humans is inactivated.
 - 6. The composition of claim 1, further comprising a tumor-associated antigen.
- 7. The composition of claim 6, wherein the tumor-associated antigen is expressed on a tumor cell present in the composition.
- 8. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with human cells *ex vivo* expressing HLA-DR antigens that are allogeneic to both HLA-DR antigens on the lymphocytes.
- 9. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently

-63-

20

25

5

20

25

5

alloactivated to be effective in eliciting an anti-tumor Immunological response when administered to a human.

- 10. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human calls *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in extending life expectancy or causing progressive reduction in tumor mass when administered to a human having a tumor.
- 11. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IFN-γ by the alloactivated lymphocytes is highest.
- 12. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IL-2 by the alloactivated lymphocytes is highest.
- 13. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells ex Am for between about 12 hours and 5 days.
- 14. The composition of claim 1, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for between about 24 and 72 hours.
 - 15. A kit comprising components of the composition of claim 1 in separate containers.
- 16. A device for treatment of a tumor in a human patient, containing the composition of claim 1.
 - 17. The device of claim 16, which is an injection needle.

10

20

5

- 18. The device of claim 16, which is suitable for positioning by ultrasound guided endoscopy.
- 19. A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 1.
 - 20. A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 1.
 - 21. A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.
 - 22. A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.
 - 23. The method of claim 19, wherein the pharmaceutical composition is administered at or around the site of a solid tumor in the patient.
 - 24. The method of claim 21, wherein the pharmaceutical composition is administered at a site distal to the tumor.